Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THX-130
- Development stage
- Discontinued
- Lead developer
- SciSparc
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
THX-130 is a proprietary, ultra-low dose formulation of dronabinol (delta-9-tetrahydrocannabinol or THC) developed by Therapix Biosciences. The drug targets microvascular injuries and associated disorders using a unique low-dose platform. It was designed for neuroprotection and microvascular protection, with potential applications in cognitive impairment disorders, traumatic brain injury (TBI), and conditions involving blood-brain barrier damage. The formulation utilizes doses ranging from 10-400 micrograms of THC, significantly lower than typical therapeutic doses. The drug was later transferred to SciSparc Ltd. but has since been discontinued.
02
Targets
CB (Cannabinoid receptors)
Beyond the preview
Go deeper on THX-130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THX-130.